ERBB2 and neoplasm: Its coordinated expression with NLRP3, particularly in HER2+ tumors, points to a potential ALKBH7–NLRP3 co-expression that could shape the tumor microenvironment dynamics and serve as a prognostic biomarker or therapeutic target, especially in aggressive subtypes such as HER2+ and TNBC.